Pamedic Moment | Jonathan Sackier in Interview, “Dedicated to Cancer Treatment for Chinese”

Jonathan Sackier, the Chief Medical Officer of Pamedic Holdings Limited（hereinafter “PMHL”）:We will deepen our collaboration with Shenzhen and the entire China, dedicated to providing innovative treatment solutions for 8 million Chinese and even global cancer patients.

Exclusive Interview of Jonathan Sackier

At The  World Science and Technology Development Forum in Shenzhen, Jonathan Sackier shared insights on innovative research and development in the field of isotope therapy. He also said that efforts are being made to make such isotopes more applicable to improve treatment outcomes for cancer patients. He added, Shenzhen has always stood for innovation and progress, and I am deeply excited and inspired every time I come here.

Isotope therapy is a cutting-edge medical technology that can precisely target cancer cells and minimize damage to normal cells. By working closely with China, it will provide more effective and safer treatment options for the majority of cancer patients.

We, Pamedic Holdings, a research and development company in the field of isotope nuclear medicine, will continue to be dedicated to advancing innovation and development in the field of isotope nuclear medicine with exerting our professional strengths. Giving ear to needs of patients, we will partner with the global medical community, research institutions and industrial partners to facilitate the innovation and development of isotope therapy technology.

Pamedic Holdings

Pamedic Holdings, co-founded by Hong Kong C Cheng Holdings Limited, MWA.T Industrial Consulting Company and UK-based PMHL Company in Loop Park, Futian District, Shenzhen, is a company specializing in technology development and production in the field of medical isotope nuclear medicine, aimming at advancing innovation in the field of nuclear medicine.  Top talents in the isotope field from both China and the UK gathered in Pamedic Holdings as its core technology team.